Stephanie Graff, MD, FACP, FASCO· @DrSGraff · X·· 2 days agoScore70
Body
HORIZON-Breast06 confirms benefit of trastuzumab *rezetecan* in a DB06-like patient population—HER2low, chemo-naive
#ESMO26 @OncoAlert
572 views · 12 likes · 9 reposts · 0 replies
Conference abstracts
LBA13matched by Proffered paper 1: Breast cancer, early and advanced stage
Trastuzumab rezetecan (SHR-A1811) in HER2-low advanced breast cancer (BC): A randomized, phase 3 study (HORIZON-Breast06)
https://esmocongress.esmo.orgSource: Stephanie Graff, MD, FACP, FASCO · x.com